{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:40:08Z","timestamp":1759174808103,"version":"3.44.0"},"reference-count":30,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J NeuroIntervent Surg"],"accepted":{"date-parts":[[2021,5,12]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Poor patient outcomes after aneurysmal subarachnoid hemorrhage (SAH) occur due to a multifactorial process, mainly involving cerebral inflammation (CI), delayed cerebral vasospasm (DCVS), and delayed cerebral ischemia, followed by neurodegeneration. CI is mainly triggered by enhanced synthesis of serotonin (5-HT), prostaglandin F2alpha (PGF2a), and cytokines such as interleukins. Levosimendan (LV), a calcium-channel sensitizer, has already displayed anti-inflammatory effects in patients with severe heart failure. Therefore, we wanted to elucidate its potential anti-inflammatory role on the cerebral vasculature after SAH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Experimental SAH was induced by using an experimental double-hemorrhage model. Sprague Dawley rats were harvested on day 3 and day 5 after the ictus. The basilar artery was used for isometric investigations of the muscular media tone. Vessel segments were either preincubated with LV or without, with precontraction performed with 5-HT or PGF2a followed by application of acetylcholine (ACh) or LV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After preincubation with LV 10<jats:sup>\u22124<\/jats:sup> M and 5-HT precontraction, ACh triggered a strong vasorelaxation in sham segments (LV 10<jats:sup>\u22124<\/jats:sup> M, E<jats:sub>max<\/jats:sub> 65%; LV 10<jats:sup>\u22125<\/jats:sup> M, E<jats:sub>max<\/jats:sub> 48%; no LV, E<jats:sub>max<\/jats:sub> 53%). Interestingly, SAH D3 (LV 10<jats:sup>\u22124<\/jats:sup>, E<jats:sub>max<\/jats:sub> 76%) and D5 (LV 10<jats:sup>\u22124<\/jats:sup>, E<jats:sub>max<\/jats:sub> 79%) segments showed greater vasorelaxation compared with sham. An LV series after PGF2a precontraction showed significantly enhanced relaxation in the sham (P=0.004) and SAH groups (P=0.0008) compared with solvent control vessels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>LV application after SAH seems to beneficially influence DCVS by antagonizing 5-HT- and PGF2a-triggered vasoconstriction. Considering this spasmolytic effect, LV might have a role in the treatment of SAH, additionally in selected patients suffering takotsubo cardiomyopathy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/neurintsurg-2021-017504","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T14:50:50Z","timestamp":1622040650000},"page":"408-412","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage?"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-5741","authenticated-orcid":false,"given":"Stefan","family":"Wanderer","sequence":"first","affiliation":[{"name":"Neurosurgery, Kantonsspital Aarau AG, Aarau, Switzerland"},{"name":"Cerebrovascular Research Group, Department for BioMedical Research, University of Bern, Bern, Switzerland"},{"name":"Neurosurgery, Goethe University Hospital, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Andereggen","sequence":"additional","affiliation":[{"name":"Neurosurgery, Kantonsspital Aarau AG, Aarau, Switzerland"},{"name":"Cerebrovascular Research Group, Department for BioMedical Research, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mrosek","sequence":"additional","affiliation":[{"name":"Neurosurgery, Goethe University Hospital, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepide","family":"Kashefiolasl","sequence":"additional","affiliation":[{"name":"Neurosurgery, Goethe University Hospital, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-6042","authenticated-orcid":false,"given":"Gerrit Alexander","family":"Schubert","sequence":"additional","affiliation":[{"name":"Neurosurgery, Kantonsspital Aarau AG, Aarau, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-7571","authenticated-orcid":false,"given":"Serge","family":"Marbacher","sequence":"additional","affiliation":[{"name":"Neurosurgery, Kantonsspital Aarau AG, Aarau, Switzerland"},{"name":"Cerebrovascular Research Group, Department for BioMedical Research, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Konczalla","sequence":"additional","affiliation":[{"name":"Neurosurgery, Goethe University Hospital, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"2025092911585716000_14.4.408.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186496","article-title":"The role of losartan as a potential neuroregenerative pharmacological agent after aneurysmal subarachnoid haemorrhage","volume":"21","author":"Wanderer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025092911585716000_14.4.408.2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.589275"},{"key":"2025092911585716000_14.4.408.3","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10030153","article-title":"The role of sartans in the treatment of stroke and subarachnoid hemorrhage: a narrative review of preclinical and clinical studies","volume":"10","author":"Wanderer","year":"2020","journal-title":"Brain Sci"},{"key":"2025092911585716000_14.4.408.4","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5024"},{"key":"2025092911585716000_14.4.408.5","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-015-0970-2","article-title":"Immune cells subpopulations in cerebrospinal fluid and peripheral blood of patients with aneurysmal subarachnoid hemorrhage","volume":"4","author":"Moraes","year":"2015","journal-title":"Springerplus"},{"key":"2025092911585716000_14.4.408.6","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9100249","article-title":"Systemic and CSF interleukin-1\u03b1 expression in a rabbit closed cranium subarachnoid hemorrhage model: an exploratory study","volume":"9","author":"Croci","year":"2019","journal-title":"Brain Sci"},{"key":"2025092911585716000_14.4.408.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2004.10.008"},{"key":"2025092911585716000_14.4.408.8","first-page":"665","article-title":"May levosimendan be safe and effective in refractory vasospasm despite adequate treatment with repeated angiography and milrinone infusion after subarachnoid haemorrhage?","volume":"38","author":"Cottenceau","year":"2019","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2025092911585716000_14.4.408.9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00701-016-2939-5","article-title":"Levosimendan, a new therapeutic approach to prevent delayed cerebral vasospasm after subarachnoid hemorrhage?","volume":"158","author":"Konczalla","year":"2016","journal-title":"Acta Neurochir"},{"key":"2025092911585716000_14.4.408.10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1567202615666180328121025","article-title":"Levosimendan reduces prostaglandin F2a-dependent vasoconstriction in physiological vessels and after experimentally induced subarachnoid hemorrhage","volume":"15","author":"Wanderer","year":"2018","journal-title":"Curr Neurovasc Res"},{"key":"2025092911585716000_14.4.408.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00872.x"},{"key":"2025092911585716000_14.4.408.12","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000199346.74649.66"},{"key":"2025092911585716000_14.4.408.13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/mf.2004.26.4.831333","article-title":"Experimental approaches to evaluate endothelin-A receptor antagonists","volume":"26","author":"Vatter","year":"2004","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2025092911585716000_14.4.408.14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10143-017-0887-z","article-title":"Crosstalk between the angiotensin and endothelin system in the cerebrovasculature after experimental induced subarachnoid hemorrhage","volume":"41","author":"Wanderer","year":"2018","journal-title":"Neurosurg Rev"},{"key":"2025092911585716000_14.4.408.15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00857.2007"},{"key":"2025092911585716000_14.4.408.16","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.23.1.54"},{"key":"2025092911585716000_14.4.408.17","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1980.53.4.0480"},{"key":"2025092911585716000_14.4.408.18","first-page":"1064","article-title":"Alteration of the cerebrovascular function of endothelin B receptor after subarachnoidal hemorrhage in the rat","volume":"231","author":"Konczalla","year":"2006","journal-title":"Exp Biol Med"},{"key":"2025092911585716000_14.4.408.19","doi-asserted-by":"publisher","DOI":"10.1016\/0090-3019(87)90037-1"},{"key":"2025092911585716000_14.4.408.20","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e3282f357a5"},{"key":"2025092911585716000_14.4.408.21","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-014938"},{"key":"2025092911585716000_14.4.408.22","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-015335"},{"key":"2025092911585716000_14.4.408.23","article-title":"Aspirin treatment prevents inflammation in experimental bifurcation aneurysms in New Zealand white rabbits","author":"Wanderer","year":"2021","journal-title":"J Neurointerv Surg"},{"key":"2025092911585716000_14.4.408.24","doi-asserted-by":"publisher","DOI":"10.2174\/1568016054368232"},{"key":"2025092911585716000_14.4.408.25","first-page":"1","article-title":"Predictors of the development of takotsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage and outcomes in patients with intra-aortic balloon pumps","author":"Catapano","year":"2020","journal-title":"J Neurosurg"},{"key":"2025092911585716000_14.4.408.26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.722868"},{"key":"2025092911585716000_14.4.408.27","doi-asserted-by":"publisher","DOI":"10.2174\/15672026113109990030"},{"key":"2025092911585716000_14.4.408.28","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.5.955"},{"key":"2025092911585716000_14.4.408.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233176","article-title":"Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels","volume":"15","author":"Rieg","year":"2020","journal-title":"PLoS One"},{"key":"2025092911585716000_14.4.408.30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10557-018-6838-2","article-title":"Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application","volume":"32","author":"Bouchez","year":"2018","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Journal of NeuroInterventional Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/neurintsurg-2021-017504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:59:03Z","timestamp":1759172343000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnis.bmj.com\/lookup\/doi\/10.1136\/neurintsurg-2021-017504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,18]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/neurintsurg-2021-017504"],"URL":"https:\/\/doi.org\/10.1136\/neurintsurg-2021-017504","relation":{},"ISSN":["1759-8478","1759-8486"],"issn-type":[{"type":"print","value":"1759-8478"},{"type":"electronic","value":"1759-8486"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}